BRPI1008014A2 - domínio variável simples, ligante multiespecífico, antagonistas de tnfr1, e de receptor de tnf-alfa, uso do agonista de tnfr, antagonista anti-tnfr1, polipeptídeo ou ligante multiespecífico, método para tratar e/ou prevenir uma condição ou doença, ácido nucleico, vetor, e, hospedeiro - Google Patents

domínio variável simples, ligante multiespecífico, antagonistas de tnfr1, e de receptor de tnf-alfa, uso do agonista de tnfr, antagonista anti-tnfr1, polipeptídeo ou ligante multiespecífico, método para tratar e/ou prevenir uma condição ou doença, ácido nucleico, vetor, e, hospedeiro

Info

Publication number
BRPI1008014A2
BRPI1008014A2 BRPI1008014A BRPI1008014A BRPI1008014A2 BR PI1008014 A2 BRPI1008014 A2 BR PI1008014A2 BR PI1008014 A BRPI1008014 A BR PI1008014A BR PI1008014 A BRPI1008014 A BR PI1008014A BR PI1008014 A2 BRPI1008014 A2 BR PI1008014A2
Authority
BR
Brazil
Prior art keywords
tnfr1
multispecific ligand
tnf
polypeptide
vector
Prior art date
Application number
BRPI1008014A
Other languages
English (en)
Portuguese (pt)
Inventor
Adrianns Allart Stoop
Armin Sepp
Carolyn Enever
Haiqun Liu
Oliver Schon
Stephen Duffield
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of BRPI1008014A2 publication Critical patent/BRPI1008014A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
BRPI1008014A 2009-02-19 2010-02-17 domínio variável simples, ligante multiespecífico, antagonistas de tnfr1, e de receptor de tnf-alfa, uso do agonista de tnfr, antagonista anti-tnfr1, polipeptídeo ou ligante multiespecífico, método para tratar e/ou prevenir uma condição ou doença, ácido nucleico, vetor, e, hospedeiro BRPI1008014A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15374609P 2009-02-19 2009-02-19
US24119809P 2009-09-10 2009-09-10
PCT/EP2010/052005 WO2010094720A2 (en) 2009-02-19 2010-02-17 Improved anti-tnfr1 polypeptides, antibody variable domains & antagonists

Publications (1)

Publication Number Publication Date
BRPI1008014A2 true BRPI1008014A2 (pt) 2016-10-04

Family

ID=42136168

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1008014A BRPI1008014A2 (pt) 2009-02-19 2010-02-17 domínio variável simples, ligante multiespecífico, antagonistas de tnfr1, e de receptor de tnf-alfa, uso do agonista de tnfr, antagonista anti-tnfr1, polipeptídeo ou ligante multiespecífico, método para tratar e/ou prevenir uma condição ou doença, ácido nucleico, vetor, e, hospedeiro

Country Status (14)

Country Link
US (1) US20110301335A1 (enExample)
EP (1) EP2398827A2 (enExample)
JP (2) JP2012517818A (enExample)
KR (1) KR20110119806A (enExample)
CN (1) CN102405236A (enExample)
AU (1) AU2010215479B2 (enExample)
BR (1) BRPI1008014A2 (enExample)
CA (1) CA2750477A1 (enExample)
EA (1) EA022925B1 (enExample)
IL (1) IL214648A0 (enExample)
MX (1) MX2011008799A (enExample)
SG (1) SG173173A1 (enExample)
WO (1) WO2010094720A2 (enExample)
ZA (1) ZA201105627B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9028822B2 (en) * 2002-06-28 2015-05-12 Domantis Limited Antagonists against TNFR1 and methods of use therefor
WO2010094723A2 (en) 2009-02-19 2010-08-26 Glaxo Group Limited Improved anti-serum albumin binding variants
WO2011008814A2 (en) 2009-07-14 2011-01-20 Immune Tolerance Institute, Inc., A California Not-For-Profit Corporation Multiplexed measurement of exogenous and endogenous dna
JP2012532619A (ja) * 2009-07-16 2012-12-20 グラクソ グループ リミテッド Ｔｎｆｒ１を部分的に阻害するためのアンタゴニスト、用途および方法
PE20121564A1 (es) * 2009-10-27 2012-11-29 Glaxo Group Ltd Polipeptidos anti-tnfr1 estables, dominios variables de anticuerpos y antagonistas
AU2011254559B2 (en) * 2010-05-20 2014-09-04 Glaxo Group Limited Improved anti-serum albumin binding variants
CN103249742B (zh) * 2010-09-16 2017-04-12 巴利奥医药股份公司 抗人肿瘤坏死因子1型受体抗体
US20140112929A1 (en) * 2011-06-17 2014-04-24 Glaxo Group Limited Tumour necrosis factor receptor 1 antagonists
WO2015104322A1 (en) 2014-01-09 2015-07-16 Glaxosmithkline Intellectual Property Development Limited Treatment of inflammatory diseases with non-competitive tnfr1 antagonists
US9815886B2 (en) 2014-10-28 2017-11-14 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
WO2016094309A1 (en) * 2014-12-10 2016-06-16 Myosotis Inhibition of tnf signaling in cancer immunotherapy
NO2768984T3 (enExample) * 2015-11-12 2018-06-09
CN107043413A (zh) * 2016-02-05 2017-08-15 华中农业大学 一种肺结核相关的尿液生物标志蛋白及其应用
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
JP7315968B2 (ja) * 2019-01-31 2023-07-27 積水メディカル株式会社 生物学的試料中の遊離ａｉｍの免疫学的分析方法及び対象におけるｎａｓｈの検出方法
US12472266B2 (en) 2019-02-21 2025-11-18 Enosi Therapeutics Corporation Antibodies and enonomers
WO2022047243A1 (en) 2020-08-27 2022-03-03 Enosi Life Sciences Corp. Methods and compositions to treat autoimmune diseases and cancer
WO2022117569A1 (en) 2020-12-02 2022-06-09 Oncurious Nv A ccr8 antagonist antibody in combination with a lymphotoxin beta receptor agonist antibody in therapy against cancer
WO2025021184A1 (zh) * 2023-07-27 2025-01-30 上海复宏汉霖生物医药有限公司 编码尿酸氧化酶的多核苷酸及其相关组合物和方法
WO2025049818A1 (en) 2023-08-29 2025-03-06 Enosi Therapeutics Corporation Tnfr1 antagonists lacking agonist activity and uses thereof

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
GB8725529D0 (en) 1987-10-30 1987-12-02 Delta Biotechnology Ltd Polypeptides
WO1989007142A1 (en) 1988-02-05 1989-08-10 Morrison Sherie L Domain-modified constant region antibodies
EP1541682A3 (en) 1988-09-02 2005-07-06 Dyax Corp. Generation and selection of recombinant varied binding proteins
ATE92107T1 (de) 1989-04-29 1993-08-15 Delta Biotechnology Ltd N-terminale fragmente von menschliches serumalbumin enthaltenden fusionsproteinen.
US5977307A (en) 1989-09-07 1999-11-02 Alkermes, Inc. Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
WO1994026087A2 (en) 1993-05-14 1994-11-24 Connor Kim C O Recombinant protein production and insect cell culture and process
WO1994029351A2 (en) 1993-06-16 1994-12-22 Celltech Limited Antibodies
ES2283936T3 (es) 1997-07-07 2007-11-01 Medical Research Council Procedimiento de clasificacion in vitro.
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
CA2399388A1 (en) 2000-02-11 2001-08-16 Michael J. Lenardo Identification of a domain in the tumor necrosis factor receptor family that mediates pre-ligand receptor assembly and function
CA2447851C (en) 2001-06-28 2012-08-28 Domantis Limited Dual-specific ligand and its use
US20080108560A1 (en) 2002-03-05 2008-05-08 Eli Lilly And Company Heterologous G-Csf Fusion Proteins
US20060002935A1 (en) * 2002-06-28 2006-01-05 Domantis Limited Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
EP1517921B1 (en) 2002-06-28 2006-06-07 Domantis Limited Dual specific ligands with increased serum half-life
US9321832B2 (en) * 2002-06-28 2016-04-26 Domantis Limited Ligand
WO2004041862A2 (en) 2002-11-08 2004-05-21 Ablynx N.V. Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
EP1578801A2 (en) 2002-12-27 2005-09-28 Domantis Limited Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
GB0230203D0 (en) 2002-12-27 2003-02-05 Domantis Ltd Fc fusion
JP4889493B2 (ja) 2003-05-14 2012-03-07 ドマンティス リミテッド ポリペプチドレパートリーから可逆的にアンフォールドするポリペプチドを回収するための方法
SI1639011T1 (sl) 2003-06-30 2009-04-30 Domantis Ltd Pegilirana protitelesa z enojno domeno (dAb)
EP1729795B1 (en) 2004-02-09 2016-02-03 Human Genome Sciences, Inc. Albumin fusion proteins
ES2351509T3 (es) 2004-03-24 2011-02-07 Domantis Limited Secuencia lider universal de gas1.
GB0418651D0 (en) 2004-08-20 2004-09-22 Medical Res Council Method
CN101084014A (zh) * 2004-10-08 2007-12-05 杜门蒂斯有限公司 抗肿瘤坏死因子受体1的单域抗体及其使用方法
GB0521621D0 (en) 2005-10-24 2005-11-30 Domantis Ltd Tumor necrosis factor receptor 1 antagonists for treating respiratory diseases
CN101454344A (zh) * 2005-12-01 2009-06-10 杜门蒂斯有限公司 与白细胞介素-1受体1型结合的非竞争性域抗体形式
JP2009518024A (ja) * 2005-12-06 2009-05-07 ドマンティス リミテッド Ｅｇｆｒおよび／またはｖｅｇｆに対して結合特異性を有するリガンドおよびその使用法
GB0724331D0 (en) 2007-12-13 2008-01-23 Domantis Ltd Compositions for pulmonary delivery
EA200901494A1 (ru) * 2007-06-06 2010-06-30 Домантис Лимитед Способы селекции протеазоустойчивых полипептидов
US7868885B2 (en) 2007-06-22 2011-01-11 Microsoft Corporation Direct manipulation of subdivision surfaces using a graphics processing unit
JP2012532619A (ja) * 2009-07-16 2012-12-20 グラクソ グループ リミテッド Ｔｎｆｒ１を部分的に阻害するためのアンタゴニスト、用途および方法
CN102574914A (zh) * 2009-07-16 2012-07-11 葛兰素集团有限公司 改进的抗血清清蛋白结合性单可变区
PE20121564A1 (es) * 2009-10-27 2012-11-29 Glaxo Group Ltd Polipeptidos anti-tnfr1 estables, dominios variables de anticuerpos y antagonistas

Also Published As

Publication number Publication date
AU2010215479A1 (en) 2011-08-25
EP2398827A2 (en) 2011-12-28
CA2750477A1 (en) 2010-08-26
KR20110119806A (ko) 2011-11-02
WO2010094720A2 (en) 2010-08-26
SG173173A1 (en) 2011-08-29
CN102405236A (zh) 2012-04-04
AU2010215479B2 (en) 2015-01-22
ZA201105627B (en) 2013-01-30
WO2010094720A3 (en) 2011-01-13
JP2012517818A (ja) 2012-08-09
IL214648A0 (en) 2011-09-27
MX2011008799A (es) 2011-09-27
EA201190116A1 (ru) 2012-06-29
JP2016007218A (ja) 2016-01-18
US20110301335A1 (en) 2011-12-08
EA022925B1 (ru) 2016-03-31

Similar Documents

Publication Publication Date Title
BRPI1008014A2 (pt) domínio variável simples, ligante multiespecífico, antagonistas de tnfr1, e de receptor de tnf-alfa, uso do agonista de tnfr, antagonista anti-tnfr1, polipeptídeo ou ligante multiespecífico, método para tratar e/ou prevenir uma condição ou doença, ácido nucleico, vetor, e, hospedeiro
BR112012025101A2 (pt) compostos antagonistas seletivos de receptor nk-3, composição farmacêutica e métodos para uso em distúrbios mediados por receptores nk-3
BR112013008255A2 (pt) anticorpo isolado ou um fragmento funcional do mesmo, uso de um anticorpo isolado ou de um fragmento funcional do mesmo, composição farmacêutica, polinucleotídeo, vetor, célula transformada, e, método para produzir anticorpo
BR112014003679A2 (pt) domínio variável de imunoglobina único, composição farmacêutica, uso de um domínio variável de imonuglobina único, método de tratamento ou prevenção de pelo menos uma doença ou distúrbio ou condição, formulação, dispositivo de dispensação, ácido nucleico isaldo ou recombinante, vetor, célula hospedeira, e, método para produzir um polipeptídeo
BRPI1008060A2 (pt) Agonistas e antagonistas do receptor s1p5, e métodos de uso do mesmo.
BRPI1006134A2 (pt) anticorpo ou um fragmento funcional do anticorpo, composição farmacêutica, uso de um anticorpo ou um fragmento funcional do mesmo, polinucleotídeo, vetor, e, célula hospedeira transformada.
IL221620A (en) Antagonist antibodies against the interleukin receptor 7 and methods for their use
BR112014004168A2 (pt) anticorpo biespecífico, composição farmacêutica, uso do anticorpo biespecífico, célula hospedeira procariótica ou eucariótica, método de produção de anticorpo e invenção
PT2547679E (pt) Derivados de 2,3-di-hidro-1h-indeno-1-il-2,7-diazaspiro[3.6]nonano e sua utilização como antagonistas ou agonistas inversos do receptor de grelina
BRPI1008441A2 (pt) anticorpo humanizado, composição farmacêutica, método para tratar e prevenir um distúrbio de célula b em sujeito, composição de anticorpo anti-cd-20 humanizado, ácido nucléico isolado e célula hospedeira.
PL3270957T3 (pl) Nowy kompleks zawierający peptyd penetrujący komórkę, cargo i agonistę peptydu tlr do leczenia glioblastomy
BR112014016076A2 (pt) peptídeo, vetor, contrução de peptídeo quimérico, ácido nucleico e uso dos mesmos e composição farmacêutica
BRPI1011413A2 (pt) sistema, método e marcador luminescente para geração de imagem luminescente difusa melhorada ou tomografia em meio de dispersão
BR112013001571A2 (pt) composto, composição farmacêutica, uso e método de prevenção ou tratamento de uma condição associada com a função do receptor gpr40
BR112013004782A2 (pt) sistema de resistência de fluxo variável para utilização em um poço subterrâneo
BR112013004359A2 (pt) fluido de furo de poço, e método para distribuir material particulado abaixo do terreno
EP2417748A4 (en) SYSTEMS, METHODS AND APPARATUS FOR CONTINUOUS TRANSMISSION OF MULTIMEDIA FILES
BRPI0813216A2 (pt) Inibidores de proteínas cinases e métodos para usá-los.
BRPI0919377A2 (pt) anticorpo isolado ou um fragmento ligante de antígeno do memso, ácido nucleico isolado, vetor, célula hospedeira, composição farmacêutica, método de produzir o referido anticorpo ou fragmento, uso dos mesmos, e composição compreendendo o referido anticorpo ou fragmento
BRPI0916964A2 (pt) polipetídeo, anticorpo, ácido nucléico, vetor, célula hospedeira, método para produzir um polipeptídeo, composição e uso do polipeptídeo
BRPI1009419A2 (pt) mistura asfaltica, e metodo de pavimentacao
BR112012030515A2 (pt) sistema para determinar o teor de asfalteno de óleo bruto, e método para determinar o teor de asfalteno de óleo bruto.
BRPI0818352A2 (pt) Polímeros em emulsão, dispersões aquosas e processos para preparar os mesmos
BR112014002265A2 (pt) sistema e método para caracterização de subsuperfície incluindo estimativa de incerteza
BR112012026174A2 (pt) anticorpo isolado, ácido nucleico isolado, vetor, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, doença ou disfunção, uso do anticorpo, método de tratamento, de determinação e de separação

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B15K Others concerning applications: alteration of classification

Ipc: C07K 16/28 (2006.01), C07K 16/18 (2006.01), A61K 3

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2449 DE 12-12-2017 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B350 Update of information on the portal [chapter 15.35 patent gazette]